Kornimate/medical-research-clean huggingface dataset:
probiotics for the prevention of antibiotics associated diarrhea in the pediatric intensive care unit

Conditions: Critical Illness; Antibiotic-associated Diarrhea

Summary: the goal of this prospective trial is to learn about lactobacillus use in critically ill pediatric patients. the main question\[s\] it aims to answer are: * is lactobacillus gg effective in preventing antibiotic associated diarrhea in the picu * is lactobacillus safe in critically ill pediatric patients participants will be randomized to lactobacillus gg vs placebo while on antibiotics if there is a comparison group: researchers will compare lactobacillus gg to see if it prevents antibiotic associated diarrhea.

the objective of this study was to assess the efficacy of lactobacillus gg (lgg) to prevent antibiotic-associated diarrhea (aad) in the picu. design: prospective randomized, double-blind, placebo-controlled trial setting: 15-20 bed picu at university of south alabama, children's and women's hospital in mobile, alabama. patients: pediatric patients ≤ 17 years and required antibiotic therapy ≥ 72hrs were randomized to receive placebo or control (lactobacillus gg). exclusion criteria included but was not limited to antibiotics ≥ 48 hours prior, prior probiotics, pre-existing diarrhea, laxative therapy, immunocompromise, and gi disorders. interventions: treatment with lgg (30 x 109 cfu) or a matching placebo capsule was administered twice daily, initiated within 24 hours of starting antibiotic therapy and continued for the duration of therapy. measurements: diarrhea was defined as stools \>200 ml or 200 g per day in a patient over 10 kg and \> 20 ml/kg/day or \> 20 g/kg/day in a patient \< 10 kg or 3 or more loose stools in 24 hours.

Eligibility criteria:
inclusion criteria: * admitted to picu * requiring \> 72 hrs of antibiotic therapy * \< 17 years * able to administer oral lgg or placebo exclusion criteria: * antibiotics 48 hours prior to hospital admission * probiotic use within 7 days of admission * pre-existing diarrhea at time of hospital admission or 24 hours prior to admission * laxative therapy at time of admission or 48 hours prior to admission * hiv with cd4 \< 250 * established immunologic deficiencies (anc \< 100) * chronic steroid therapy ( \> 10 days) * gi disorders including intussusception, lower bowel disease, bowel resection, irritable bowel syndrome, ulcerative colitis, or crohn's disease * status post-surgical patients with antibiotic prophylaxis (\< 72 hours duration) * npo

Keywords: pediatric picu
study of a bone assessment technique, bone mineral analyser, concerning the prediction of improvement in bone status after an infusion of zoledronic acid in osteoporotic women

Conditions: Osteoporosis

Summary: * collection of epidemiological data * biological assessment as part of routine care. * measurement of the hurst coefficient at d0 * measurement of bone density and tbs on d0 * zoledronic acid infusion the month following inclusion * phone call at 1 month (observance of zoledronic acid) * measurement of bone density, calculation of the hurst coefficient at m12


Eligibility criteria:
inclusion criteria: * women \< 85 years old * postmenopausal women (amenorrhea for more than 12 months), a confirmation diagnosis should be obtained (amenorrhea for at least 12 months before the inclusion visit). * post-menopausal osteoporosis with one or more severe fractures (upper end of the humerus, femur, or tibia; 3 adjacent ribs; lower end of the femur; thoracic or lumbar spine; pelvis), or t score \<-3 which justifies setting up a bisphosphonate treatment * affiliated to social security exclusion criteria: * contraindication to zoledronic acid (allergy to the product, creatinine clearance \<35 ml / min, hypocalcemia, open and unhealed lesions of the soft tissues of the mouth) * hormone replacement therapy taken in the last 12 months * osteoprotective treatment (bisphosphonates, teriparatide, raloxifene, strontium ralenate or denosumab) taken in the last 12 months * secondary osteoporosis: hyperthyroidism, hyperparathyroidism, long-term corticosteroid therapy, hypercorticism, hypogonadism, treatment with anti aromatases / lhrh analogues, neoplastic pathology (solid or hemopathy) * history of bilateral wrist or femur fracture * person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curatorship * patient participating in another trial / having participated in another trial within 6 months
combined buprenorphine and behavioral treatment with and without contingent reinforcement on opioid and cocaine abstinence. - 22

Conditions: Cocaine-Related Disorders; Opioid-Related Disorders

Summary: the purpose of this study is to test combined buprenorphine and behavioral treatment with and without contingent reinforcement on opioid and cocaine abstinence.


Eligibility criteria:
please contact site for information.
dengue seroprevalence study in blood donors in the french west indies

Conditions: Blood Donors; Dengue

Summary: dengue is an infectious disease most prevalent in the world. this disease is endemic in the caribbean, with an increase in seasonal rains. several outbreaks have been observed in recent years, in 2001, 2005 and 2007, during which further particularly virulent serotypes have emerged. the clinical expression of dengue fever is variable, ranging from no symptoms to a classical form with fever, and even of severe or lethal bleeding. with the possible existence of silent forms of the disease, there are no data identifying the current level of protection of the population in martinique / guadeloupe.

1. principal objective: to estimate the prevalence of the specific antibodies of the dengue (igg) in blood donors in the french west indies. 2. secondary objective: to specify the serotypic specificity of the anti-dengue antibodies detected during the study.

Eligibility criteria:
inclusion criteria: * eligible for blood donation following the french legislation, * resident in martinique /guadeloupe for at least one year * consent signed exclusion criteria: * not eligible for blood donation following the french legislation, * not resident in martinique / guadeloupe for at least one year * consent not signed
lamelleye vs comparator for the treatment of dry eye disease

Conditions: Dry Eye Syndromes

Summary: single-blind, randomised, single centre, 2-way crossover study to collect post-market clinical follow-up data on the ce-marked lamelleye dry eye drops medical device.

the study is a 2-way crossover design comprising 2 treatments: the ce-marked lamelleye dry eye drops, and a ce-marked comparator product. all participants will be allocated to a treatment group in a random order. this study design allows observations to be made between the treatments at both an intra- and inter-patient level regarding relationships between the patients' disease specific quality of life, symptoms and adverse events.

Eligibility criteria:
inclusion criteria: 1. participant has provided written informed consent. 2. male or female participants ≥ 18 and ≤ 79 years of age. 3. participant has dry eye disease as diagnosed from positive responses to non-invasive tear break-up time (nitbut) (≤10 seconds); schirmer test (≤10mm in 5 minutes); and patient symptoms (\>2 symptoms using the mcmonnies dry eye questionnaire) 4. participant must understand and be able, willing and likely to fully comply with study procedures and restrictions. exclusion criteria: 1. active ocular infection 2. ocular surgery within 6 months of study start date 3. current contact lens wear 4. any ophthalmologic drops within 1 week prior to enrolment that in the opinion of the ci or pi may interfere with the study outcomes. 5. started or changed the dose of chronic systemic medication known to affect tear production including, but not limited to antihistamines, anticholinergics, antidepressants, diuretics, corticosteroids or immunomodulators within 30 days of initial visit. 6. systemic disease known to affect tear production or loss including, but not limited to thyroid eye disease, that has been diagnosed or has not been stable within 30 days of visit 1. 7. known hypersensitivity to any of the agents used in testing such as allergies to egg or soya based products. 8. females who are or wish to become pregnant
survey: evaluation of ocular surface disease symptoms and patient satisfaction with thealoz® duo after 84 days of daily treatment

Conditions: Dry Eye

Summary: multi-centre, international, non-interventional, prospective survey

to assess after 84 days, on a large scale patient population, the evaluation of ocular surface diseases and the satisfaction of dry eye disease (ded) treatment naïve patients or those who had to switch for tolerance, dissatisfaction or efficacy reasons to thealoz® duo.

Eligibility criteria:
inclusion criteria: * all dry eye patients who require artificial tears or need to change their current artificial tears for any reason (i.e. due to dissatisfaction or low efficacy, etc...) * outpatients of either sex, aged at least 18 years * patients informed of the objectives of the survey and agreeing to participate. exclusion criteria: * use of cyclosporine, lifitegrast, tacrolimus, sirolimus within last 3 months and during the survey * use of topical ophthalmological treatments (glaucoma, etc...) * use of lacrimal plugs * ocular surgery in the last 12 months * concomitant use of corticosteroids * concomitant use of autologous serum or any blood derivatives * severe blepharitis * severe dry eye associated to * eyelid malposition * corneal dystrophy * ocular neoplasia * sjogren syndrome * any systemic pathologies * pregnancy/lactation
the effect of cetirizine on bronchoconstriction

Conditions: Allergic Rhinitis; Asthma

Summary: the purpose of this study is to determine the effect of cetirizine, an oral antihistamine, on wheezing in patients with allergic rhinitis. patients presenting to the pediatric emergency department who have a history of allergic rhinitis and who are wheezing will be asked to participate. half of patients will receive a dose of cetirizine and the other half will receive placebo and their response will be monitored over the course of their emergency department visit with vital signs, physical examinations, and measurement of bronchoconstriction with spirometry.

this is a prospective randomized, placebo-controlled trial to look at the effect of cetirizine on bronchoconstriction in patients with allergic rhinitis who present to the pediatric emergency department with wheezing. oral second generation antihistamines such as cetirizine are already the standard of care for allergic rhinitis. wheezing pediatric patients with allergic rhinitis who are not already on this therapy will be randomized to receive either age-appropriate-dosed cetirizine or placebo in addition to standard asthma therapy at the discretion of the treating clinician, and will be monitored every 30 minutes with asthma scores and fev1 measurements. at the conclusion of 3 hours, each patient who received placebo will receive a dose of cetirizine, and each patient who received cetirizine will receive a placebo medication dose, such that initiating therapy for allergic rhinitis is delayed by no more than 3 hours.

Eligibility criteria:
inclusion criteria: * history of allergic rhinitis * wheezing exclusion criteria: * use of antihistamine within the past 72 hours * chronic pulmonary condition other than asthma * other contraindication to cetirizine * severe asthma exacerbation requiring resuscitation
correlation between hemochron and istat in cardiac surgery (chic study)

Conditions: Cardiac Event

Summary: cardiac surgery needs the use of cardiopulmonary bypass. during this time, it is necessary to prevent thrombosis with high level of heparin and to control the good efficiency with a point of care test. investigators want to test if two different devices, hemochron and istat, are giving similar results.

the management of the extracorporeal circulation (ecc) for cardiac surgery requires massive anticoagulation of the circuit by heparinization at 300 iu / kg of unfractionated heparin (hnf). to ensure an adequate level of safety, it is necessary to monitor the effectiveness of this dose of nhf. several point of care monitors measuring activated coagulation time (act) are available on the market. among these are the hemochron (currently used routinely in the institution) and the istat. these two monitors have been compared in adult cardiac surgery without deep hypothermia, but there is no comparative study in pediatric cardiac surgery. the result of the act being dependent, in addition to heparinization, the platelet count, the fibrinogen level and the body temperature, it is therefore necessary to test the approval and the interchangeability between the monitors in different clinical situations . the objective of this study is to reproduce the results published in adults and to compare these two monitors in pediatrics.

Eligibility criteria:
inclusion criteria: * adults or children * supported in the department of anesthesia - resuscitation of the louis pradel hospital (lyon, france) for cardiac surgery with or without cardiopulmonary bypass * patient or parents / holders of parental authority informed and not opposed to participate in the study exclusion criteria: * patient with heparin-induced thrombocytopenia * patient receiving antiplatelet therapy targeting gpiibiiia receptors
risk factors identification of sepsis and septic shock after major abdominal surgery based on artificial intelligence

Conditions: Sepsis; Postoperative Complications

Summary: the goal of this observational study is to identify the risk factors and build the early warning system of sepsis and septic shock after major abdominal surgery based on artificial intelligence. the main questions it aims to answer are: what are the high risk factors of postoperative sepsis? which factors can accelerate the progression of sepsis? researchers will collect perioperative characteristics to construct predictive models of postoperative sepsis in a retrospective abdominal surgical population based on artificial intelligence, and the accuracy of the models were tested in an external dataset.


Eligibility criteria:
inclusion criteria： 1. patients undergoing major abdominal surgery. 2. the surgeon performing the operation has extensive experience in specialized surgeries such as upper gastrointestinal, hepatobiliary and pancreatic, colorectal, gynecological, and urological surgeries, having completed at least 50 corresponding specialized surgical cases. 3. the anesthesiologist performing the operation has more than 5 years of clinical experience. 4. all surgical patients receive general anesthesia. 5. patients are aged ≥ 18 years. exclusion criteria： 1. pregnancy-related surgeries (cesarean section, abortion surgery). 2. patients with known preoperative infection or suspected infection. 3. severely malnourished patients (bmi reference values are 17 kg/m² for patients \ 70 years old). 4. patients who have previously undergone abdominal surgery. 5. patients without sufficient data, including demographic variables (such as age, gender), surgical details (surgery duration, surgical grade, anesthesia grade, anesthesia duration), and hospitalization details (such as icu stay, in-hospital mortality).
effects of ghrelin administration on motivation

Conditions: Major Depressive Disorder

Summary: everyday humans are confronted with a plethora of rewards competing for their attention. nevertheless, to obtain a goal or reward, humans often need to invest effort. when humans are confronted with the challenge to integrate costs of action such as the effort of walking to one's favorite lunch place with its anticipated benefits (i.e., eating one's favorite meal), accumulating evidence suggest that humans might "go with the gut". ghrelin is a stomach-derived hormone and the only known circulating peptide that stimulates appetite. at the same time, patients with major depressive disorder report deficits in motivated behavior which are oftentimes accompanied by changes in appetite and weight. based on a wealth of accruing evidence from animal studies, the investigators suggest that the gut acts as an important arbitrator in effort allocation by signaling the energy level of the body. within this physiological framework, ghrelin is thought to signal a short-term energy deficit to increase reward responsivity and willingness to work for reward as compensatory (allostatic) means. here, the investigators propose to conduct a follow-up study (to nct05318924) with subcutaneous administration of ghrelin vs. saline in patients with major depressive disorder and healthy control participants. during each visit, participants will receive a subcutaneous administration of either ghrelin or saline and perform an effort allocation task where they have to exert physical effort to obtain food and monetary rewards. the investigators hypothesize that ghrelin will increase the motivation to exert effort for rewards. the goal of this follow-up study is to test that the motivational effects of ghrelin are similar in patients with depression and healthy control participants. furthermore, participants resting energy expenditure will be estimated before and after the administration. in line with a role of ghrelin as an energy deficit signal, the investigators expect ghrelin to decrease energy expenditure. during each visit, participants will answer questions about their current mood and physiological state. the investigators hypothesize that ghrelin increases mood state and hunger while decreasing satiety.


Eligibility criteria:
inclusion criteria: \* must have participated in the behavioral study arm of nct05120336 exclusion criteria: * participation in the neuroimaging part of nct05120336 * breastfeeding * pregnancy

Keywords: energy homeostasis motivation ghrelin anhedonia mood
validity and reliability of the turkish version of the tegner activity score

Conditions: Knee Injuries

Summary: the goal of this observational study is to learn about patients who will undergo anterior cruciate ligament reconstruction. the main questions it aims to answer are: * is the turkish version of the tegner activity score a valid scale? * is the turkish version of the tegner activity score a reliable scale? * what is the minimal clinically important difference value of the turkish version of the tegner activity score? * what is the substantial clinical benefit value of the turkish version of the tegner activity score?


Eligibility criteria:
inclusion criteria: * to be over 18 years old * to undergo surgery for a ruptured anterior cruciate ligament exclusion criteria: * to have metabolic or autoimmune diseases * to undergo revision anterior cruciate ligament surgery or anterior cruciate ligament repair * to have cognitive issues that will hinder the completion of the study forms * to lack sufficient proficiency in turkish

Keywords: tegner activity score anterior cruciate ligament injury validity reliability patient reported outcome
monoclonal antibody therapy or biological therapy in treating patients with chronic lymphocytic leukemia or multiple myeloma in remission after chemotherapy

Conditions: Leukemia; Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. biological therapies such as interferon alfa-2b use different ways to stimulate the immune system and stop cancer cells from growing. purpose: phase ii trial to study the effectiveness of rituximab or interferon alfa-2b in treating patients who have chronic lymphocytic leukemia or multiple myeloma in remission.

objectives: i. determine the toxicity of rituximab or interferon alfa-2b maintenance therapy in patients with chronic lymphocytic leukemia or multiple myeloma in remission after chemotherapy. ii. determine the progression free survival, failure free survival, and overall survival of these patients from time of chemotherapy discontinuation to completion of maintenance therapy. iii. compare the survival rates of these patients to similar patients treated in published studies. iv. determine the quality of life of these patients on these regimens. outline: patients enter one of two treatment arms: arm i: patients receive rituximab iv on days 1, 8, 15, and 22 for course 1, and then once a month for 11 months or until disease progression. arm ii: patients receive subcutaneous interferon alfa-2b every other day three times per week for 12 months. quality of life is assessed monthly during therapy. patients are followed every 3 months for 1 year, and then annually for up to 5 years. projected accrual: a total of 60-80 patients (30-40 per disease type) will be accrued for this study.

Eligibility criteria:
disease characteristics: b-cell chronic lymphocytic leukemia or multiple myeloma in remission that was previously treated with chemotherapy without disease progression patient characteristics: age: not specified performance status: ecog 0-2 life expectancy: not specified hematopoietic: lymphocyte count less than 10,000/mm3 hepatic: not specified renal: not specified other: not pregnant or nursing fertile patients must use effective contraception no active infection or other concurrent lifethreatening disease medical condition satisfactory for treatment with chemotherapy prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics endocrine therapy: not specified radiotherapy: not specified surgery: not specified

Keywords: stage i multiple myeloma stage ii multiple myeloma stage iii multiple myeloma stage i chronic lymphocytic leukemia stage ii chronic lymphocytic leukemia stage iii chronic lymphocytic leukemia stage iv chronic lymphocytic leukemia b-cell chronic lymphocytic leukemia
low-volume oral carbohydrate feeding in bariatric surgery: effects on ponv and recovery

Conditions: Bariatric Surgery; Postoperative Nausea and Vomiting

Summary: this randomized controlled trial aims to evaluate the effects of preoperative oral administration of 200 ml 12.5% carbohydrate solution on postoperative nausea, vomiting, and recovery in bariatric surgery patients. the intervention group received carbohydrate loading two hours before surgery. outcomes were measured using the rhodes index of nausea, vomiting and retching (rinvr) and the postoperative recovery index (pori).

this randomized controlled trial was designed to evaluate the effects of preoperative low-volume oral carbohydrate loading on postoperative nausea, vomiting, and recovery in patients undergoing bariatric surgery. a total of 105 adult patients scheduled for bariatric surgery were randomized into two groups: an intervention group (n = 53) and a control group (n = 52). the intervention group received 200 ml of a 12.5% carbohydrate solution orally two hours before surgery, while the control group followed standard preoperative fasting protocols without receiving any carbohydrate supplementation. the primary hypothesis was that preoperative low-volume carbohydrate loading would reduce the frequency and severity of postoperative nausea, vomiting, and retching (ponv), and improve postoperative recovery. data were collected using validated instruments including the rhodes index of nausea, vomiting and retching (rinvr) and the postoperative recovery index (pori). outcomes were assessed within 24 hours postoperatively and at postoperative day 30. randomization was performed using computer-generated block randomization, and outcome assessment was blinded. the intervention was administered by a trained researcher, and standard postoperative nursing care protocols were applied to both groups.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * scheduled for bariatric surgery * asa score ≤ iv * literate in turkish and able to provide informed consent exclusion criteria: * use of antiemetics, steroids, or opioids within 24 hours pre-op * need for icu post-op * reoperation

Keywords: perioperative nursing bariatric surgery postoperative nausea and vomiting postoperative recovery carbohydrate feeding